Most Serious Keytruda Side Effects
Keytruda (pembrolizumab), an immunotherapy drug for cancers like melanoma and lung cancer, carries immune-related adverse events where the immune system attacks healthy tissues. The highest-risk side effects, per FDA labeling, include severe or fatal immune-mediated reactions affecting organs like lungs, intestines, liver, endocrine glands, and skin. These occur in up to 10-20% of patients for some events and require immediate medical intervention, often steroids or treatment interruption.[1][2]
Immune-Mediated Pneumonitis and Lung Issues
Pneumonitis tops the list for life-threatening risk, happening in 3-5% of patients across trials, with grade 3-4 severity in 1-2%. Symptoms: shortness of breath, cough, chest pain. Fatal cases reported in under 1%. Risk rises with combo therapies like chemotherapy.[1][3]
Colitis and Severe Diarrhea
Immune-mediated colitis strikes 1-2% severely (grade 3-4), causing bloody stools, abdominal pain, dehydration. Incidence jumps to 10%+ in some combination regimens. Can lead to bowel perforation if untreated.[1][2]
Hepatitis and Liver Damage
Elevated liver enzymes signal hepatitis in 0.7-4% at severe levels, with rare fulminant failure. Jaundice, fatigue common early signs. Higher risk in patients with hepatitis B/C history.[1]
Endocrinopathies (Thyroid, Adrenal, Pituitary)
Hypothyroidism or hyperthyroidism in 10-20%; severe adrenal insufficiency or hypophysitis in 1-5%. Type 1 diabetes (including fatal ketoacidosis) in 0.2%. Symptoms: fatigue, weight changes, low blood sugar. Often permanent hormone replacement needed.[1][3]
Other High-Risk Reactions
- Skin: Severe rash or Stevens-Johnson syndrome (<1%, but fatal possible).
- Neurologic: Encephalitis, Guillain-Barré (<1%, grade 3-4).
- Cardiac: Myocarditis (0.3-1.7%, often fatal).
- Infusion reactions: Anaphylaxis in <1%.[1][2]
Risk Factors and Monitoring
Higher incidence with PD-1/L1 combos, prior autoimmune disease, or longer treatment (>6 months). FDA black box warns of these; monitor with regular labs, imaging. Report any new symptoms immediately—early catch prevents fatality rates under 1% overall.[1][3]
How Common Are Fatal Side Effects?
Trials show immune-related deaths in 0.2-1% of patients, mostly from pneumonitis or myocarditis.[2]
Sources
[1]: FDA Keytruda Label
[2]: Keytruda Prescribing Information - Merck
[3]: NCCN Guidelines - Immunotherapy Toxicity